Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Regulus Therapeutics's RGLS-8429?
RGLS-8429 is an antisense oligonucleotide commercialized by Regulus Therapeutics, with a leading Phase I program in Polycystic Kidney Disease. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Regulus Therapeutics's RGLS-8429?
RGLS-8429 is an antisense oligonucleotide commercialized by Regulus Therapeutics, with a leading Phase I program in Polycystic Kidney Disease. According...